What is the optimal range for Lp(a)?

Standard reference range: <30 mg/dL (or <75 nmol/L) mg/dL (or nmol/L depending on assay). Optimization-focused target: <30 mg/dL - but the value is set genetically mg/dL (or nmol/L depending on assay).

Home/Biomarkers/Lp(a)

CARDIOVASCULAR BIOMARKER

Lp(a)

Q: What does Lp(a) measure?

Lp(a) is an LDL-like particle with an additional protein called apolipoprotein(a) attached. Genetically determined - your level is set by ~age 5 and doesn't change meaningfully with lifestyle. About 20% of the population has elevated Lp(a) (>50 mg/dL), which carries 2–4× higher cardiovascular risk independent of LDL or ApoB.

Lipoprotein(a)

The genetic cardiovascular risk marker - fixed for life, not lifestyle-modifiable. Tested once; if elevated, drives lifelong risk management.

STANDARD RANGE

<30 mg/dL (or <75 nmol/L)

OPTIMAL (OPTIMIZATION)

<30 mg/dL - but the value is set genetically

RANGE VISUALIZATION

How Lp(a) ranges relate

The standard lab range vs the optimization-focused target. Illustrative trajectory shows what a 12-week improvement pattern looks like — not real user data.

Standard lab rangeOptimization-focused targetIllustrative trajectory

What Lp(a) Measures

Lp(a) is an LDL-like particle with an additional protein called apolipoprotein(a) attached. Genetically determined - your level is set by ~age 5 and doesn't change meaningfully with lifestyle. About 20% of the population has elevated Lp(a) (>50 mg/dL), which carries 2–4× higher cardiovascular risk independent of LDL or ApoB.

Because it's fixed for life, you only need to test once. If elevated, the answer isn't "lower Lp(a)" (we have no good tools for that yet - though pelacarsen is in late-stage trials) - it's "be more aggressive with everything else": lower ApoB harder, blood pressure tighter, lifestyle dialed.

What Affects This Biomarker

Lp(a) is influenced by: genetics (~80–90% of variance - this is the dominant factor), kidney disease (raises modestly), pregnancy (raises), menopause (raises), hypothyroidism (raises), and very few pharmacologic agents shift it - statins barely budge it; PCSK9 inhibitors lower modestly (~25%); niacin lowers ~25%; in trials, pelacarsen and olpasiran (antisense / siRNA against apo(a)) lower 70–95% but aren't approved yet.

In the Context of Peptide Protocols

Test Lp(a) once at baseline. If <30 mg/dL: never test again, don't worry about it. If 30–75: aggressive lifestyle + tight ApoB target. If >75: discuss aggressive pharmacologic management with your cardiologist. Doesn't move with peptide protocols. The CV outcomes data on the new RNA-based therapies is the biggest story to watch in this space.

Conditions That Track Lp(a)

CARDIOVASCULAR

Elevated ApoB (Cardiovascular Risk)

When the atherogenic particle count is elevated - the single most accurate cardiovascular risk lab marker.

Track Lp(a) over time.

Upload any lab PDF and MyProtocolStack maps your values to Lp(a) and 40+ other biomarkers. StackAI interprets the trend in context of your protocol.

Start tracking →

Informational only - not medical advice. Reference ranges vary by lab and individual context. Work with a licensed provider to interpret your specific results.